Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

More than 6 million adults in the US live with plaque psoriasis, but it’s often a misunderstood disease. Joining the discussion is actress entrepreneur Lala Anthony and dermatologist Dr. Meghan ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Machine learning models may be a useful tool for psoriasis severity assessment in clinical settings, despite a need for further research.

News Obese Children Are More Likely to Develop Skin Conditions Related to the Immune System. Childhood obesity can contribute to the development of common immune-mediated skin dis ...

Accord BioPharma has received FDA approval for IMULDOSA, a biosimilar to STELARA, for treating chronic inflammatory conditions like psoriasis and Crohn's disease. Scheduled for a 2025 launch, it aims ...

Alex Thompson CFA, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Oruka Therapeutics (ORKA). Alex Thompson CFA has given ...

Brodalumab is an effective therapy among patients with psoriasis who have failed prior biologic therapy or had risk factors for treatment failure.